{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:31:43Z","timestamp":1763458303757},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10637-023-01412-0","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T06:02:19Z","timestamp":1702015339000},"page":"53-59","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis"],"prefix":"10.1007","volume":"42","author":[{"given":"Haibo","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"4","key":"1412_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"issue":"21","key":"1412_CR2","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E et al (2019) Nivolumab plus Ipilimumab in advanced non-small-cell lung Cancer. N Engl J Med 381(21):2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"issue":"4","key":"1412_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/ajco.12867","volume":"14","author":"C Tiu","year":"2018","unstructured":"Tiu C, Wong A, Herschtal A, Mileshkin L (2018) Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers. Asia Pac J Clin Oncol 14(4):337\u2013342. https:\/\/doi.org\/10.1111\/ajco.12867","journal-title":"Asia Pac J Clin Oncol"},{"issue":"10","key":"1412_CR4","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","volume":"20","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Rini BI, McDermott DF, Ar\u00e9n Frontera O, Hammers HJ, Carducci MA et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20(10):1370\u20131385. https:\/\/doi.org\/10.1016\/S1470-2045(19)30413-9","journal-title":"Lancet Oncol"},{"issue":"12","key":"1412_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.urolonc.2017.08.005","volume":"35","author":"AW Hahn","year":"2017","unstructured":"Hahn AW, Gill DM, Agarwal N, Maughan BL (2017) PD-1 checkpoint inhibition: toxicities and management. Urol Oncol 35(12):701\u2013707. https:\/\/doi.org\/10.1016\/j.urolonc.2017.08.005","journal-title":"Urol Oncol"},{"key":"1412_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"issue":"4","key":"1412_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559\u2013574. https:\/\/doi.org\/10.1093\/annonc\/mdv623","journal-title":"Ann Oncol"},{"key":"1412_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1412_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6(1):8. https:\/\/doi.org\/10.1186\/s40425-018-0316-z","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1412_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL (2020) Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep 22(4):39. https:\/\/doi.org\/10.1007\/s11912-020-0897-9","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"1412_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R et al (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer 5(1):95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"1412_CR12","doi-asserted-by":"publisher","first-page":"800879","DOI":"10.3389\/fimmu.2021.800879","volume":"12","author":"L Tang","year":"2021","unstructured":"Tang L, Wang J, Lin N, Zhou Y, He W, Liu J, Ma X (2021) Immune checkpoint inhibitor-associated colitis: from mechanism to management. Front Immunol 12:800879. https:\/\/doi.org\/10.3389\/fimmu.2021.800879","journal-title":"Front Immunol"},{"issue":"10","key":"1412_CR13","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA (2016) Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol 2(10):1346\u20131353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051","journal-title":"JAMA Oncol"},{"issue":"2","key":"1412_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and Meta-analysis. JAMA Oncol 4(2):173\u2013182. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"issue":"9","key":"1412_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1412_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40425-019-0524-1","volume":"7","author":"E Bello","year":"2019","unstructured":"Bello E, Cohen JV, Mino-Kenudson M, Dougan M (2019) Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis. J Immunother Cancer 7(1):41. https:\/\/doi.org\/10.1186\/s40425-019-0524-1","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1412_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/CJI.0000000000000435","volume":"45","author":"A Obeidat","year":"2022","unstructured":"Obeidat A, Silangcruz K, Kozai L, Wien E, Fujiwara Y, Nishimura Y (2022) Clinical characteristics and outcomes of gastritis associated with immune checkpoint inhibitors: scoping review. J Immunother 45(8):363\u2013369. https:\/\/doi.org\/10.1097\/CJI.0000000000000435","journal-title":"J Immunother"},{"key":"1412_CR18","doi-asserted-by":"publisher","first-page":"725549","DOI":"10.3389\/fonc.2021.725549","volume":"11","author":"JM Placke","year":"2021","unstructured":"Placke JM, Rawitzer J, Reis H, Rashidi-Alavijeh J, Livingstone E, Ugurel S et al (2021) Apoptotic gastritis in melanoma patients treated with PD-1-based immune checkpoint inhibition - clinical and histopathological findings including the diagnostic value of anti-Caspase-3 immunohistochemistry. Front Oncol 11:725549. https:\/\/doi.org\/10.3389\/fonc.2021.725549","journal-title":"Front Oncol"},{"issue":"4","key":"1412_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/his.14029","volume":"76","author":"M Johncilla","year":"2020","unstructured":"Johncilla M, Grover S, Zhang X, Jain D, Srivastava A (2020) Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Histopathology. 76(4):531\u2013539. https:\/\/doi.org\/10.1111\/his.14029","journal-title":"Histopathology."},{"issue":"6","key":"1412_CR20","doi-asserted-by":"publisher","first-page":"e00334","DOI":"10.1002\/rcr2.334","volume":"6","author":"T Onuki","year":"2018","unstructured":"Onuki T, Morita E, Sakamoto N, Nagai Y, Sata M, Hagiwara K (2018) Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient. Respirol Case Rep 6(6):e00334. https:\/\/doi.org\/10.1002\/rcr2.334","journal-title":"Respirol Case Rep"},{"issue":"3","key":"1412_CR21","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.4049\/jimmunol.181.3.1908","volume":"181","author":"GH Stummvoll","year":"2008","unstructured":"Stummvoll GH, DiPaolo RJ, Huter EN, Davidson TS, Glass D, Ward JM, Shevach EM (2008) Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol 181(3):1908\u20131916. https:\/\/doi.org\/10.4049\/jimmunol.181.3.1908","journal-title":"J Immunol"},{"issue":"5","key":"1412_CR22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.intimp.2009.01.022","volume":"9","author":"EN Huter","year":"2009","unstructured":"Huter EN, Stummvoll GH, DiPaolo RJ, Glass DD, Shevach EM (2009) Pre-differentiated Th1 and Th17 effector T cells in autoimmune gastritis: ag-specific regulatory T cells are more potent suppressors than polyclonal regulatory T cells. Int Immunopharmacol 9(5):540\u2013545. https:\/\/doi.org\/10.1016\/j.intimp.2009.01.022","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1412_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jcmgh.2017.03.005","volume":"4","author":"KA Bockerstett","year":"2017","unstructured":"Bockerstett KA, DiPaolo RJ (2017) Regulation of gastric carcinogenesis by inflammatory cytokines. Cell Mol Gastroenterol Hepatol 4(1):47\u201353. https:\/\/doi.org\/10.1016\/j.jcmgh.2017.03.005","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"10","key":"1412_CR24","doi-asserted-by":"publisher","first-page":"100419","DOI":"10.1016\/j.xcrm.2021.100419","volume":"2","author":"S Ferrian","year":"2021","unstructured":"Ferrian S, Liu CC, McCaffrey EF, Kumar R, Nowicki TS, Dawson DW, Baranski A, Glaspy JA, Ribas A, Bendall SC, Angelo M (2021) Multiplexed imaging reveals an IFN-\u03b3-driven inflammatory state in nivolumab-associated gastritis. Cell Rep Med 2(10):100419. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100419","journal-title":"Cell Rep Med"},{"issue":"17","key":"1412_CR25","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of Immune-Related Adverse Events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"1412_CR26","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","volume":"29","author":"JBAG Haanen","year":"2018","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2018) ESMO guidelines committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv264\u2013iv266. https:\/\/doi.org\/10.1093\/annonc\/mdy162","journal-title":"Ann Oncol"},{"issue":"4","key":"1412_CR27","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/ecco-jcc\/jjv227","volume":"10","author":"L Marthey","year":"2016","unstructured":"Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F et al (2016) Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis 10(4):395\u2013401. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv227","journal-title":"J Crohns Colitis"},{"issue":"3","key":"1412_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.32074\/1591-951X-24-19","volume":"111","author":"P Gaffuri","year":"2019","unstructured":"Gaffuri P, Espeli V, Fulciniti F, Paone G, Bergmann M (2019) Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Pathologica 111(3):92\u201397. https:\/\/doi.org\/10.32074\/1591-951X-24-19","journal-title":"Pathologica"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01412-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T10:07:34Z","timestamp":1708682854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01412-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1412"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01412-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]},"assertion":[{"value":"1 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}